Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 2017

View Archived Issues

Novel beta-secretase 1/2 inhibitors identified at Merck & Co.

Lilly discovers novel phosphodiesterase PDE1 inhibitors

Amino-terminal fragment of the Par-4 protein overcomes therapy resistance in tumors

TWIST2 and SPOCK1 are essential regulators of human brain metastasis-initiating cells

Unum receives IND clearance to study ACTR-087 in combination with SEA-BCMA for multiple myeloma

Pfizer describes potent MAGL inhibitor for neuroinflammation

LE-004, an Mdm2-degrading PROTAC for the treatment of cancer

Karus initiates phase I study of HDAC6 inhibitor KA-2507 in solid tumors

FDA clears IND for phase I/II trial of Titan's ropinirole implant for Parkinson's disease

Five AstraZeneca anesthetic medicines transferred to Aspen in Canada

FDA grants orphan drug designation to SENS-401

New drug application filed for obinutuzumab in Japan

Curtana completes pre-IND meeting with the FDA regarding development of CT-179

Fujiyakuhin describes novel bisphosphonates

GPCR19 agonists patented by Universite de Droit et Sante de Lille, Institut Pasteur de Lille, INSERM

Savira, European Molecular Biology Laboratory discover novel compounds for influenza

EA Pharma divulges new TRPA1 antagonists

Ultragenyx submits BLA for burosumab to treat X-linked hypophosphatemia

Cancer Research UK initiates trial of LY-3143921 hydrate in solid tumors

Topline results from phase III study of daratumumab in front-line multiple myeloma

Bristol-Myers Squibb describes discovery of antithrombotic macrocyclic FXIa inhibitors

Bioverativ and Invicro form imaging collaboration to improve joint disease management in hemophilia

Aequus receives FDA feedback on plans to seek abbreviated 505(b)(2) pathway for AQS-1301

Apellis' phase II study of APL-2 in geographic atrophy meets primary endpoint

FDA approves Gocovri to treat dyskinesia in Parkinson's disease

FDA and EMA accept Vertex's submissions for tezacaftor/ivacaftor for cystic fibrosis

European Commission approves adalimumab biosimilar Imraldi

IDRI partners with Hisun to continue development of inhalable CPZEN-45 for TB

Protagonist Therapeutics closes license and collaboration agreement with Janssen for PTG-200

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.